Biofil Chemicals & Pharmaceuticals Ltd.
Snapshot View

70.00 +0.05 ▲0.1%

04 August 2021, 04:00:00 P.M.
Volume: 15,809

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.biofilgroup.net
Financial Indicators
Market Cap 113.92 Cr.
Earnings per share (EPS) 0.76 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 91.79 Trailing Twelve Months Ending 2021-03
Industry PE 32.74 Trailing Twelve Months Ending 2021-03
Book Value / Share 9.91 Trailing Twelve Months Ending 2021-03
Price to Book Value 7.07 Calculated using Price: 70.00
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 1.63 Cr. 16,273,800 Shares
FaceValue 10
Company Profile

Biofil Chemicals & Pharmaceuticals established in 1985, is part of Cyano Group of Industries. The company is into manufacturing of drugs in area of anti-bacterial, analgesics/antipyretics, anti-malarial, anti-psychotics, anti asthmatic/bronchodilators, diuretics, tranquilizer/hypnotics, anti inflammatory, analgesic/antipyretics, anti inflammatory steroids and eye/ear drops

Its plant is located at Plot No. 8, Sector-IV Kheda Industrial Estate, Pithampur, Dhar District, Madhya Pradesh. The facility has received GMP certificate from Licensing Authority, Food & Drugs Administration, Department of Health and Government of Madhya Pradesh, India.

The manufacturing unit exports around 30 to 40% of their formulation directly or through merchant export to countries in own or neutral labels.

The shares of companies are listed on Bombay Stock Exchange.

Company exports its products to countries namely Kenya, Uganda, Tanzania, Nigeria, U.A.E, Rwanda, Monrovia, Republic of Yemen and Mauritius.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.07%
1 Week
-0.21%
1 Month
+3.93%
3 Month
-1.48%
6 Month
-23.95%
1 Year
+193.50%
2 Year
+849.80%
5 Year
+686.52%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 5.12 16.49 13.53 13.47 13.28 18.09 3.64 3.60 8.46
Return on Capital Employed (%) 5.05 14.53 12.09 12.97 14.04 21.86 5.13 5.06 10.12
Return on Assets (%) 1.23 3.93 3.68 4.14 4.13 7.81 2.05 1.99 3.63

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 7 7 8 8 11 13 13 14 15
Non Curr. Liab.
Curr. Liab. 7 6 7 5 13 9 11 11 27
Minority Int.
Equity & Liab. 14 13 15 14 24 22 24 24 42
Non Curr. Assets 9 9 9 9 9 9 9 10 10
Curr. Assets 5 4 5 5 15 13 15 14 32
Misc. Exp. not W/O
Total Assets 14 13 15 14 24 22 24 24 42

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 6 6 7 6 13 13 12 23 30
Other Income 0 0 0 0 1 0 0 0 0
Total Income 6 6 7 6 14 14 12 23 30
Total Expenditure -6 -5 -6 -5 -12 -11 -11 -22 -28
PBIDT 0 1 1 1 1 3 1 1 2
Interest 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0
Taxation 0 0 0 0 0 -1 0 0 0
Exceptional Items
PAT 0 1 1 1 1 2 0 0 1

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 0 0 0 0 0 1 0 1 1
Cash Fr. Inv. -1 0 0 0 0 0 0 -1 0
Cash Fr. Finan. 1 0 0 0 0 0 0 0 -1
Net Change 0 0 0 0 0 0 0 0 0
Cash & Cash Eqvt 0 0 0 0 0 0 0 0 0

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 46.82 46.82 46.82 46.82 46.82 46.82 46.82 46.82 46.82
Public 53.18 53.18 53.18 53.18 53.18 53.18 53.18 53.18 53.18
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Wed, 04 Aug 2021
Board Meeting Intimation for Intimation For Board Meeting (03/2021-2022) Scheduled To Be Held On Friday 13Th August 2021 Pursuant To Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulation 2015
BIOFIL CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2021 inter alia to consider and approve With reference to above captioned subject and in terms of Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 we would like to inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday 13th August 2021 at Registered Office of the Company to transact the following matters:-
1. To consider and approve the Un-audited Financial Result of the Company for the 1st Quarter ended on 30th June 2021 along with limited review report thereon.
2. To consider matters relating to the ensuing Annual General Meeting.

Mon, 02 Aug 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to provision of Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 we submit details received from our Registrar on 31st July 2021 regarding issued duplicate share certificate.

Sat, 24 Jul 2021
Disclosure Of Related Party Transactions For The Half Year Ended 31St March 2021
Pursuant to Regulation 23(9) SEBI(Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith the Disclosure of Related party Transactions of the Company for the half year ended 31st March 2021

Technical Scans View Details

Tue, 03 Aug 2021
High Delivery Percentage High Delivery Percentage
Close Crossing Last Month Close from Above Close Crossing Last Month Close from Above
Closing Below Previous Low Closing Below Previous Low
Mon, 02 Aug 2021
High Delivery Percentage High Delivery Percentage
Close Crossing Last Month Close From Below Close Crossing Last Month Close From Below

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 188,527.75 785.75 -1.1%
Divi's Laboratories Ltd. 131,785.24 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. 79,333.82 4,768.80 +1.0%
Cipla Ltd. 75,796.16 939.65 +1.2%
Cadila Healthcare Ltd. 60,170.47 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. 58,468.59 4,066.40 -0.6%
Piramal Enterprises Ltd. 57,915.28 2,550.50 +1.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.40 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2021-03 66.41 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.66 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 31.52 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 28.20 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 388.86 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 43.47 2,550.50 +1.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.94 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2021-03 14.18 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.44 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 4.15 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 4.63 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.72 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1.69 2,550.50 +1.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 0.10 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,550.50 +1.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 14.13 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,550.50 +1.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 17.85 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,550.50 +1.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2020-03 6,969.40 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 19,159.59 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,550.50 +1.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,984.29 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 2,401.30 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,550.50 +1.7%